Two models have been proposed to select for biopsy patients at high-risk for aggressive prostate cancer amongst those with elevated PSA. These two models are evaluated on an independent data set. Model A is the standard model used in many clinics. Model B is a new model that adds in the results of new imaging test. The new test is somewhat unpleasant for patients, although far less unpleasant than a biopsy. Should we use the new model, subjecting patients to the unpleasant new test?

Model A (standard model).

AUC 0.7835

Pseudo R2 0.1445

Root MSE 0.36155

Variance of phat 0.0191445

Brier score: 0.1348

Model B (including imaging test)

AUC 0.8328

Pseudo R2 0.2026

Root MSE 0.34607

Variance of phat 0.0371363

Brier score: 0.1212